Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Pfizer : MD Anderson Cancer Center, Pfizer to Jointly Investigate Therapies for Blood Cancers, Solid Tumors

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/06/2017 | 12:13pm CEST

The University of Texas MD Anderson Cancer Center and pharmaceutical giant Pfizer say theyll jointly evaluate new combinations of three investigational immunotherapies and other agents to treat various solid tumors and blood cancers.

The clinical agreement covers five studies, for now. An MD Anderson/Pfizer joint steering committee will oversee the initiative.

Pfizers investigational therapies to be used in the trials include Bavencio (avelumab), a PD-L1 inhibitor; Glasdegib (PF-04449913), an investigational oral, smoothened (SMO) inhibitor; Mylotard (gemtuzumab ozogamicin), an antibody-drug conjugate; PF-04518600, an investigational OX40 agonist, and Utomilumab (a non-proprietary name for PF-05082566), an investigational CD137 agonist.

The first study is expected to enroll up to 188 patients with solid tumors, included in seven treatment groups of therapeutic agents alone or in combination with radiotherapy.

This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies, Dr. Aung Naing, associate professor of investigational cancer therapeutics at Houston-based MD Anderson and head of the solid tumor program, said in a press release. The studies are designed to hone in on specific combinations and tumor types, and explore unique mechanisms of response and resistance to immunotherapies. Our comprehensive approach will allow us to study new combinations of immunotherapy and standard therapies for patients with solid tumors in need of new treatment options.

The second study, designed to enroll 159 patients with acute myeloid leukemia (AML), will have eight different treatment arms. In addition, three other studies will evaluate Pfizer agents in blood cancer patients.

This series of Phase 1b trials will involve an accelerated series of combination immunotherapy trials for acute myeloid leukemia (AML) and solid tumors, said Dr. Naval Daver, associate professor of leukemia at MD Anderson and leading investigator at the blood cancer clinical trial. Our aim is to deliver new therapeutic solutions to our patients through this uniquely designed clinical trial program.

Most of the trials are anticipated to be initiated before the end of 2017.

Pfizer believes that meaningful treatment advancements for patients with blood cancers will come from novel combinations of immuno-oncology agents and targeted therapies, said Dr. Chris Boshoff, senior vice-president and head of immuno-oncology, early development and translational oncology at Pfizer. We are delighted to work with MD Anderson one of the worlds best cancer research institutions to explore unique combinations that may have a significant impact for patients.

(c) International 2006-2017, SANA Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:31pLIZ BARRETT, NOVARTIS : ‘My personal mission is to help find cures for can..
AQ
04:30pHow U.S. tax reform rewards companies that shift profit to tax havens
RE
06/16PFIZER : WHO approves Ghana trachoma free
AQ
06/16PFIZER : The New York Academy of Medicine Honors Dr. Freda Lewis-Hall, Dr. Ruth ..
AQ
06/15ViiV Healthcare`s two-drug HIV regimen successful in late-stage studies; Glax..
AQ
06/15PFIZER : John Witzig Named to NBAA Board of Directors
AQ
06/15NOVO NORDISK A/S : Keynote Speakers Announced for 2018 Annual Meeting & Expo
AQ
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
AQ
06/14PFIZER : New Findings from Pfizer in the Area of Algorithms Reported (Time Serie..
AQ
06/14PFIZER : Study Data from Pfizer Provide New Insights into Macular Edema (A CCR2/..
AQ
More news
News from SeekingAlpha
11:23aFDA accepts Myriad Genetics' application for BRACAnalysis CDx as companion di.. 
08:40aDIVIDEND PORTFOLIO REVIEW : New Dividend Record 
06/14ViiV Healthcare's two-drug HIV regimen successful in late-stage studies; Glax.. 
06/13With Mylan's Neulasta Biosimilar Approval, Focus Moves To Advair And Restasis 
06/13SANGAMO THERAPEUTICS : Investibility Outlook 
Financials ($)
Sales 2018 54 404 M
EBIT 2018 20 780 M
Net income 2018 12 874 M
Debt 2018 21 840 M
Yield 2018 3,76%
P/E ratio 2018 16,72
P/E ratio 2019 15,13
EV / Sales 2018 4,31x
EV / Sales 2019 4,13x
Capitalization 213 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,9 $
Spread / Average Target 9,6%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER0.39%212 690
JOHNSON & JOHNSON-12.25%328 858
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880
AMGEN6.39%122 422